Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET

Company Participants

Stephanie Fagan – Chief Corporate Affairs Officer
Rob Barrow – Chief Executive Officer
Dan Karlin – Chief Medical Officer

Conference Call Participants

Madhu Yennawar – Leerink Partners
James Nevin – RBC Capital Markets
Charles Duncan – Cantor
Francois Brisebois – Oppenheimer
Patrick Trucchio – H.C. Wainwright
Michael Okunewitch – Maxim Group
Sumant Kulkarni – Canaccord Genuity

Operator

Good afternoon, and welcome to Mind Medicine Third Quarter 2024 Financial Results and Corporate Update Conference Call. Currently all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of MindMed's website at mindmed.co and a recording will be available after the call.

I would like to introduce Stephanie Fagan, Chief Corporate Affairs Officer at MindMed. Please go ahead.

Stephanie Fagan

Thank you, operator. Good afternoon, everyone. Thank you for joining us today for a discussion of MindMed's third quarter 2024 business highlights and financial results. Leading the call today will be Rob Barrow, our Chief Executive Officer. He will be joined by Dr. Dan Karlin, our Chief Medical Officer; and Francois Lilienthal, our Chief Commercial Officer.

After our prepared remarks, we will open the call for Q&A. An audio recording and webcast replay for today's conference call will also be available online as detailed in the press release announcement for this call.

During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy and regulatory and clinical progress of our product candidates, our anticipated cash runway and future expectations, plans, partnerships and prospects. These statements are subject to various risks such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC and the applicable Canadian securities regulators, including our annual report on Form 10-K and our Form 10-Q filed today.

Forward-looking statements are based on the assumptions, opinions and estimates of management at the date the statements are made, including the nonoccurrence of the risks and uncertainties that are described in the filings made with the SEC and the applicable Canadian securities regulators or other significant events occurring outside of MindMed's normal course of business. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, November 7, 2024. MindMed disclaims any obligation to update such statements even if management's views change, except as required by law.